BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 6438498)

  • 1. Mechanism of inhibition of natural killing by a glycopeptide isolated from the K562 plasma membrane.
    Targan S; Decker JM; Ades EW
    Nat Immun Cell Growth Regul; 1983-1984; 3(3):113-23. PubMed ID: 6438498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on the mechanism of natural killer cell-mediated cytotoxicity. IV. Interferon-induced inhibition of NK target cell susceptibility to lysis is due to a defect in their ability to stimulate release of natural killer cytotoxic factors (NKCF).
    Wright SC; Bonavida B
    J Immunol; 1983 Jun; 130(6):2965-8. PubMed ID: 6189909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence of a dynamic role of the target cell membrane during the early stages of the natural killer cell lethal hit.
    Deem RL; Targan SR
    J Immunol; 1984 Jul; 133(1):72-7. PubMed ID: 6427347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on the mechanism of the human natural killer cell lethal hit: analysis of the mechanism of protease inhibition of the lethal hit.
    Hiserodt JC; Britvan L; Targan SR
    J Immunol; 1983 Dec; 131(6):2705-9. PubMed ID: 6358352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potassium channels in human NK cells are involved in discrete stages of the killing process.
    Sidell N; Schlichter LC; Wright SC; Hagiwara S; Golub SH
    J Immunol; 1986 Sep; 137(5):1650-8. PubMed ID: 2427578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of altered membrane structure on NK cell-mediated cytotoxicity. III. Decreased susceptibility to natural killer cytotoxic factor (NKCF) and suppression of NKCF release by membrane rigidification.
    Roozemond RC; Mevissen M; Urli DC; Bonavida B
    J Immunol; 1987 Sep; 139(5):1739-46. PubMed ID: 3624869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on the mechanism of the human natural killer cell lethal hit: evidence for transfer of protease-sensitive structures requisite for target cell lysis.
    Hiserodt JC; Britvan LJ; Targan SR
    J Immunol; 1983 Dec; 131(6):2710-3. PubMed ID: 6358353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of altered membrane fluidity on NK cell-mediated cytotoxicity. I. Selective inhibition of the recognition or post recognition events in the cytolytic pathway of NK cells.
    Roozemond RC; Bonavida B
    J Immunol; 1985 Apr; 134(4):2209-14. PubMed ID: 3855929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of human natural killer soluble cytotoxic factors (NKCF) derived from NK-enriched lymphocyte populations: specificity of generation and killing.
    Farram E; Targan SR
    J Immunol; 1983 Mar; 130(3):1252-6. PubMed ID: 6822733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the lethal hit stage of natural killer cell-mediated cytotoxicity. I. Both phorbol ester and ionophore are required for release of natural killer cytotoxic factors (NKCF), suggesting a role for protein kinase C activity.
    Graves SS; Bramhall J; Bonavida B
    J Immunol; 1986 Sep; 137(6):1977-84. PubMed ID: 2427588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of cell-mediated cytotoxicity at the single cell level. VI. Direct assessment of the cytotoxic potential of human peripheral blood non-lytic effector-target cell conjugates.
    Bonavida B; Lebow LT; Bradley TP
    J Immunol; 1984 Feb; 132(2):594-8. PubMed ID: 6606675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on the mechanism of natural killer cytotoxicity. II. coculture of human PBL with NK-sensitive or resistant cell lines stimulates release of natural killer cytotoxic factors (NKCF) selectively cytotoxic to NK-sensitive target cells.
    Wright SC; Weitzen ML; Kahle R; Granger GA; Bonavida B
    J Immunol; 1983 May; 130(5):2479-83. PubMed ID: 6833762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IFN-gamma treatment of K562 cells inhibits natural killer cell triggering and decreases the susceptibility to lysis by cytoplasmic granules from large granular lymphocytes.
    Grönberg A; Ferm MT; Ng J; Reynolds CW; Ortaldo JR
    J Immunol; 1988 Jun; 140(12):4397-402. PubMed ID: 3131433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of human NK cell cytotoxicity against K562 cells with glycopeptides from K562 plasma membranes.
    Decker JM; Hinson A; Ades EW
    J Clin Lab Immunol; 1984 Nov; 15(3):137-43. PubMed ID: 6397595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. K562 killing by K, IL 2-responsive NK, and T cells involves different effector cell post-binding trigger mechanisms.
    Shanahan F; Brogan MD; Newman W; Targan SR
    J Immunol; 1986 Jul; 137(2):723-6. PubMed ID: 3487579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on the mechanism of natural killer cell-mediated cytotoxicity. VII. functional comparison of human natural killer cytotoxic factors with recombinant lymphotoxin and tumor necrosis factor.
    Wright SC; Bonavida B
    J Immunol; 1987 Mar; 138(6):1791-8. PubMed ID: 3493288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of inhibition of human natural killer activity by ultraviolet radiation.
    Weitzen ML; Bonavida B
    J Immunol; 1984 Dec; 133(6):3128-32. PubMed ID: 6491282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Definition of a "trigger" stage in the NK cytolytic reaction sequence by a monoclonal antibody to the glycoprotein T-200.
    Targan SR; Newman W
    J Immunol; 1983 Sep; 131(3):1149-53. PubMed ID: 6886418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human natural killer cytotoxic factor. Studies on its production, specificity, and mechanism of interaction with target cells.
    Blanca I; Herberman RB; Ortaldo JR
    Nat Immun Cell Growth Regul; 1985; 4(1):48-59. PubMed ID: 4033671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential substages of natural killer cell-derived cytolytic factor (NKCF)-mediated cytolysis as defined by glutaraldehyde modulation of the target cell.
    Deem RL; Targan SR
    J Immunol; 1984 Oct; 133(4):1836-40. PubMed ID: 6432901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.